

Ministry of Higher education and scientific research University of Baghdad Al-kindy college of medicine

Prevalence of abnormal blood incidence in heart failure patients

Students (research group):

Tabark Haider Mahdi Jumana Alaa Abbas Tabark Haider Karim Mahdi Saleh Kazem

Supervised by:

Dr.Rayan Zaidan Physiology department/Al-kindy college of medicine/ University of Baghdad

2023 A.D 1444 H.D



Abstract:

<u>Introduction:</u> Heart failure means that the heart isn't pumping as well as it should. The body depends on the heart's pumping action to deliver oxygen- and nutrient-rich blood to the body's cells. With heart failure, the weakened heart can't supply the cells with enough blood. With a lot of complications: Irregular heart rhythms, liver and kidney damage, lung dysfunction and loss of energy.

Objectives:

- ➤ Understande Pathophysiology HF.
- ➤ prognostic blood indices in heart failure.

<u>Methods:</u> The study was Conducted in AL-Kindy College of medicine University of Baghdad, from december 2020_2023 April. 100 patient sample collected from AL-kindy teaching hospital and IBN-Nfees hospital. The number of male74 and female 26. And the mean age 59.9. We get information needed from patient's file in the hospital and Archives .Analysis using a statistical package for social sciences (spss) was applied on the collected data.

Result:

- That there is significant decrease in(RBC, PLT, HGB, HCT, MCV, MCH, MCHC, PDW) values (the mean difference was negative).
- That there is significant increase in (WBC, RDW, MPV) values (the mean difference was positive).
- (

Conclusions:

- Anaemia is highly prevalent in patients with HF particularly, in the elderly and in females.
- higher degree of thrombocytopenia is associated with higher all-cause mortality.
- High RDW is associated with a high mortality rate in HF patients.

<u>Recommendations:</u> Further studies among other hospitals and societies are needed about the effects of heart failure on kidney functions or lung functions.

List of content

Abstract......3

Introduction..... 5

Material and methods.9.

Results..... 10

Discussion...... 44

Conclusions...... 46

Limitations...47.

Recommendations...... 51

References..... 52.

questioner. 54

Introduction:

Heart failure, also known as congestive heart failure (CHF), is a progressive

condition that serves as a common endpoint for various forms of cardiac disease. It carries an extremely poor prognosis (Braunwald, 2008) **[3]** (Mayo Clinic)**[4]**. While the term heart failure may imply a complete cessation of heart function, it actually refers to a situation where the heart is unable to pump blood as effectively as it should. Although congestive heart failure is often used interchangeably with heart failure, it specifically denotes a type of heart failure that requires timely medical attention (American Heart Association, 2016) **[1]**. The body relies on the heart's pumping action to deliver oxygen- and nutrient-rich blood to the cells. In heart failure, the weakened heart fails to supply adequate blood to meet the body's needs. This results in symptoms such as fatigue, shortness of breath, and excessive coughing. Even simple everyday activities like walking, climbing stairs, or carrying groceries can become challenging (American Heart Association, 2016) **[1]**. Etiology:

Most cases of heart failure stem from systolic dysfunction, which refers to inadequate myocardial contractile function resulting from conditions like ischemic heart disease. However, heart failure can also arise from diastolic dysfunction, characterised by the heart's inability to relax and fill properly. Valve dysfunction, abnormal load burden, and increased tissue demands are additional causes of heart failure (Braunwald, 2008) [3][4].

Pathophysiology:

In response to reduced myocardial contractility or increased hemodynamic burden, the cardiovascular system employs several homeostatic mechanisms:

- The Frank-Starling mechanism plays a role in heart failure compensation, where increased end-diastolic filling volumes lead to cardiac dilation and enhanced contraction, thereby increasing cardiac output. However, ventricular dilation increases wall tension and oxygen requirements, eventually leading to decompensated heart failure (Braunwald, 2008) [3].
- Activation of neurohumoral systems, including the release of norepinephrine, activation of the renin-angiotensin-aldosterone system, and release of atrial natriuretic peptide, further compensates for heart

failure by increasing heart rate, augmenting myocardial contractility, and regulating fluid balance (Braunwald, 2008) [3].

• Myocardial structural changes, such as augmented muscle mass, also occur in response to increased workloads. In pressure overload states like hypertension, the ventricular wall thickness increases (concentric hypertrophy), while volume overload states like valvular regurgitation can cause ventricular dilation with variable wall thickness. However, these compensatory changes increase myocardial oxygen demands and make the myocardium vulnerable to ischemic injury. Pathological cardiac hypertrophy is associated with increased mortality and is an independent risk factor for sudden cardiac death (Braunwald, 2008) [3].

Left-Sided Heart Failure:

The primary causes of left-sided cardiac failure include ischemic heart disease, systemic hypertension, mitral or aortic valve disease, and primary myocardial diseases like amyloidosis. Dyspnea on exertion is usually the earliest and most significant symptom of left- sided heart failure, along with coughing due to fluid transudation into air spaces. As heart failure progresses, patients may experience orthopnea (dyspnea when recumbent) and paroxysmal nocturnal dyspnea, characterised by breathlessness that awakens them from sleep. Other clinical features include an enlarged heart, tachycardia, a third heart sound (S3), and fine rales at the lung bases (Braunwald, 2008) **[3].**

Right Side heart failure:

Pure right-sided heart failure is associated with systemic and portal venous congestion, leading to manifestations such as hepatic and splenic enlargement, peripheral edema, pleural effusion, and ascites (Braunwald, 2008) [3].

Isolated right-sided heart failure also can occur in a few diseases. The most common of these is severe pulmonary hypertension, resulting in right-sided heart pathology termed cor pulmonale. In cor pulmonale, myocardial hypertrophy and dilation generally are confined to the right ventricle and atrium, although bulging of the ventricular septum to the left can cause left ventricular dysfunction. Isolated right sided failure also can occur in patients with primary pulmonic or tricuspid valve disease. Complications of Heart Failure:

Heart failure can give rise to several complications that further impact overall health and well-being. And these complications are:

- Irregular Heart Rhythms: When the heart struggles to pump blood effectively, it can result in arrhythmias, which are irregular heartbeats. Arrhythmias disrupt the coordinated contraction of the heart chambers, impairing blood flow and oxygen delivery throughout the body (American Heart Association, 2020) [2].
- Liver and Kidney Damage: Heart failure can lead to reduced blood supply to vital organs like the liver and kidneys, impairing their normal functioning. Insufficient blood flow can result in liver and kidney damage over time, affecting their ability to filter waste products and maintain overall homeostasis (Braunwald, 2008) [3].
- Lung dysfunction: Congestive heart failure can interfere with the efficient movement of blood into and out of the lungs. This can cause blood to accumulate in the lungs, leading to pulmonary edema (fluid buildup in the air sacs), making breathing more difficult (American Heart Association, 2016) [1].
- Loss of Energy: Inadequate oxygen delivery to the body's tissues due to heart failure can result in a significant loss of energy. Individuals may experience fatigue, weakness, and an inability to engage in physical activities that require exertion (American Heart Association, 2016) [1].

Objectives:

1-knowledge the types and causes of HF.

2- Understanding Pathophysiology HF.

3-knowledge what is the symptom, complication, treatment and diagnosis of HF.

4- prognostic blood indices in heart failure.

Material and methods:

This Cross sectional study was Conducted in AL-Kindy College of medicine-University of Baghdad in december 2020_ 2023April. patients sample 100 collected from AL-kindy Teaching hospital and IBN-Nfees hospital. Exclusion criteria are the following :

- arrhythmias patient
- Ischemic heart disease patient
- Pulmonary embolism
- Obesity patient
- Diabetes mellitus

Sampling methods a convenience sample type of non probability sampling, Type of sampling is known availability sampling.

Method of data collection:

The data were collected from both genders at different ages, but the most elderly male, the number of the male is 74 and the number of female is 26. We get information needed from the patient's file in the hospital and also take data from Archives. The patients were lying in the ccu (coronary care unit). Every patient subjected to clinical and physical examination had ECG, Chest x ray, Echo study to confirm heart failure and investigations were done to them including CBC.

statistical methods :

The data were analysed using the statistical package for social sciences (spss) statistics version 29.0.0.0 (241)and microsoft Excel version 2010. Tables and figures will be used. We calculated the mean and standard deviations for CBC values of patients and explained the distribution on graphs. Independent sample t test was used to exclude effect of sex on CBC values in our sample, and chi-square test was used to exclude effect age on result in our sample. One sample t test was used for the patient's CBC values by using normal population mean to see if there is any change in the CBC of the heart failure patient values compared with normal population.

P value <0.05 used to be the level of significance.





Chart(1)







The RBC Values(×10^6/uL):







The WBC Values(×10^3/uL):

Continuous Field Information WBC(×10^3/uL)



The PLT Values(×10^3/uL):

Continuous Field Information PLT(×10^3/uL)



The HGB Values(g/dL):

Continuous Field Information HGB(g/dL)



The HCT Values(%):

Chart(14):

The MCV Values(fL):

Continuous Field Information MCV(fL)

The MCH Values(pg):

Continuous Field Information MCH(pg)

The MCHC Values(g/dL):

The RDW Values(%):

Continuous Field Information RDW(%)

The MPV Values(fL):

The PDW Values(%):

Continuous Field Information PDW(%)

The Effect Of The Gender Of The Patients On The Result:

Independent Samples T Test:

		Leve	ene's						
		Test	for						
		Equal	ity of						
		Varia	inces						
		F	Si	t	df	Signif	icance	Mean	Std.
			g.			One-	Two	Differ	Error
			0			Side	_	ence	Differen
						dn	Side	•	Ce
						up	dn		
	Equal variances	6.13	01	461	08	373	<u>646</u>	08070	17527
(-10)	Equal variances	0.13	.01	.401	90	.323	.0 - 0	.08079	.1/32/
6/uL)	assumed	2	3						
	Equal variances not			.590	76.2	.279	<mark>. 557</mark>	.08079	.13705
	assumed				63		100		
WBC(×10^	Equal variances	.056	.81	1.32	98	.094	<mark>.189</mark>	1.3490	1.01900
3/uL)	assumed		3	4				5	
	Equal variances not			1.39	48.0	.085	<mark>.171</mark>	1.3490	.97033
	assumed			0	89			5	
PLT(×10^3	Equal variances	.509	.47	-	98	.443	.887	-	19.2774
/nL)	assumed		7	.143				2.7564	
(uL)	Equal variances not				37.1	110	898		21 3459
	assumed			129	36	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	.070	2 7564	21.5457
$UCD(\alpha/dI)$	Equal variances	2 22	07	1.00	00	127	274	5065	4607
поь(g/uL)	Equal variances	3.22	.07	1.09	98	.157	.2/4	.3003	.4007
	assumed	2	0	9	57.1	100	216	50.65	10.50
	Equal variances not			1.25	57.1	.108	<mark>.216</mark>	.5065	.4050
	assumed			1	97				
HCT(%)	Equal variances	3.38	.06	1.14	98	.127	<mark>.254</mark>	1.5818	1.37956
	assumed	9	9	7				9	
	Equal variances not			1.33	60.4	.093	<mark>.187</mark>	1.5818	1.18460
	assumed			5	52			9	
MCV(fL)	Equal variances	.022	.88	1.30	98	.098	<mark>.196</mark>	2.3397	1.7964
	assumed		3	2					
	Equal variances not			1 31	44 3	098	.197	2 3 3 9 7	1 7846
	assumed			1	33				
MCH(ng)	Equal variances	048	82	1.26	98	105	210	8115	6426
men(pg)	assumed	.010	.02	3	70	.105		.0115	.0120
	Equal variances not		,	1.26	12 7	107	21/	9115	6424
	Equal variances not			1.20	43.7	.107	.217	.0115	.0454
MOUC(-/4	assumed Examination of a	146	70	2(7	07	205	700	0010	2442
MCHC(g/a	Equal variances	.146	./0	.267	98	.395	.790	.0918	.3442
L)	assumed		3		10.5		700		
	Equal variances not			.266	43.5	.396	<mark>.792</mark>	.0918	.3455
	assumed				15				
RDW(%)	Equal variances	.510	.47	-	98	.041	<mark>.082</mark>	-	.6277
	assumed		7	1.76				1.1046	
				0					
	Equal variances not			-	44.7	.041	.082	-	.6205
	assumed			1.78	43			1.1046	
				0					
MPV(fL)	Equal variances	.007	.93	-	98	.357	<mark>.714</mark>	-	.28038
. ()	assumed		4	.368				.10318	
	Equal variances not				47.0	352	704	-	26003
	assumed			382	53		., • •	10318	.20775
	Equal variances	127	72		08	120	858	- 0830	4670
1 D W(/0)	Equal variances	.12/	./2	180	90	.427	.000	0039	.4070
	Equal variances not		5	.100	40.4	125	<u> 840</u>	0020	1205
	Equal variances not			- 101	49.4	.423	.649	0839	.4385
	assumed		1	.191	8/				

Table(1)

As we see in the result of independent samples t test, all P values of our categories is larger than 0.05(alpha level) so, we will accept the null hypothesis

that there is probably no significant association between the gender of the patients and the CBC variables values in this sample of heart failure patients.

The Effect Of The Age Of The Patients On The Result:

1- For RBC values:

Chi-Square Tests				
	Value	df	Asymptotic	
			Significance	
			(2-sided)	
Pearson Chi-Square	3168.542 ^a	3200	<mark>.650</mark>	
Likelihood Ratio	641.503	3200	1.000	
Linear-by-Linear	6.797	1	.009	
Association				
N of Valid Cases	100			

Table(2)

The P value is larger than 0.05(alpha level) so, The null hypothesis will be accepted (that there is no significant association between the age of the patient and RBC value in this sample of heart failure patients).

2- For WBC values:

Chi-Square Tests				
	Value	df	Asymptotic Significance (2-sided)	
Pearson Chi-Square	3893.690 ^a	3840	<mark>.268</mark>	
Likelihood Ratio	691.777	3840	1.000	
Linear-by-Linear Association	.002	1	.967	
N of Valid Cases	100			

Table(3)

The P value is larger than 0.05(alpha level) so, The null hypothesis will be accepted (that there is no significant association between the age of the patient and WBC value in this sample of heart failure patients).

3- For PLT values:

Chi-Square Tests				
	Value	df	Asymptotic	
			Significance	
			(2-sided)	
Pearson Chi-Square	3353.770 ^a	3280	<mark>.181</mark>	
Likelihood Ratio	649.821	3280	1.000	
Linear-by-Linear	.010	1	.922	
Association				
N of Valid Cases	100			

The P value is larger than 0.05(alpha level) so, The null hypothesis will be accepted (that there is no significant association between the age of the patient and PLT value in this sample of heart failure patients).

Chi-Square Tests				
	Value	df	Asymptotic	
			Significance	
			(2-sided)	
Pearson Chi-Square	2264.595ª	2120	<mark>.015</mark>	
Likelihood Ratio	558.133	2120	1.000	
Linear-by-Linear	7.171	1	.007	
Association				
N of Valid Cases	100			

4- For HGB values:

Table(5)

The P value is smaller than 0.05(alpha level) so, The null hypothesis will be rejected (that there is significant association between the age of the patient and HGB value in this sample of heart failure patients).

Symmetric Measures					
		Value	Approximate		
			Significance		
Nominal by	Cramer'	<mark>.752</mark>	.015		
Nominal	s V				
N of Valid Cases		100			

Table(6)

As we have a high cramer's value(>0.5), there is strong association between the age of the patient and HGB value in this sample of heart failure patients.

5- For HCT values:

Chi-Square Tests				
	Value	df	Asymptotic	
			Significanc	
			e (2-sided)	
Pearson Chi-Square	3650.079 ^a	3600	<mark>.276</mark>	
Likelihood Ratio	674.095	3600	1.000	
Linear-by-Linear	7.744	1	.005	
Association				
N of Valid Cases	100			

Table(7)

The P value is larger than 0.05(alpha level) so, The null hypothesis will be accepted (that there is no significant association between the age of the patient and HCT value in this sample of heart failure patients).

6- For MCV value:

Chi-Square Tests				
	Value	df	Asymptotic	
			Significanc	
			e (2-sided)	
Pearson Chi-Square	2365.249 ^a	2200	<mark>.007</mark>	
Likelihood Ratio	542.038	2200	1.000	
Linear-by-Linear	.087	1	.768	
Association				
N of Valid Cases	100			

Table(8)

The P value is smaller than 0.05(alpha level) so, The null hypothesis will be rejected (that there is significant association between the age of the patient and MCV value in this sample of heart failure patients).

Symmetric Measures						
Value Approxima						
			Significance			
Nominal by	Cramer's V	<mark>.769</mark>	.007			
Nominal						
N of Valid Cases		100				
Table(9)						

As we have a high cramer's value(>0.5), there is strong association between the age of the patient and MCV value in this sample of heart failure patients.

7- The MCH values:

Chi-Square Tests				
	Value	df	Asymptotic	
			Significanc	
			e (2-sided)	
Pearson Chi-Square	2595.417 ^a	2520	<mark>.144</mark>	
Likelihood Ratio	585.684	2520	1.000	
Linear-by-Linear	.139	1	.709	
Association				
N of Valid Cases	100			

Table(10)

The P value is larger than 0.05(alpha level) so, The null hypothesis will be accepted (that there is no significant association between the age of the patient and MCH value in this sample of heart failure patients).

8- The MCHC values:

Chi-Square Tests				
	Value	df	Asymptotic	
			Significanc	
			e (2-sided)	
Pearson Chi-Square	2012.165 ^a	1960	<mark>.201</mark>	
Likelihood Ratio	534.906	1960	1.000	
Linear-by-Linear	.245	1	.621	
Association				
N of Valid Cases	100			

Table(11)

The P value is larger than 0.05(alpha level) so, The null hypothesis will be accepted (that there is no significant association between the age of the patient and MCHC value in this sample of heart failure patients).

9- The RDW values:

Chi-Square Tests				
	Value	df	Asymptotic	
			Significanc	
			e (2-sided)	
Pearson Chi-Square	2475.575 ^a	2400	<mark>.138</mark>	
Likelihood Ratio	578.046	2400	1.000	
Linear-by-Linear	1.673	1	.196	
Association				
N of Valid Cases	100			

Table(12)

The P value is larger than 0.05(alpha level) so, The null hypothesis will be accepted (that there is no significant association between the age of the patient and RDW value in this sample of heart failure patients).

10- The MPV values:

Chi-Square Tests							
	Value	Asymptotic					
			Significanc				
			e (2-sided)				
Pearson Chi-Square	1763.556 ^a	1680	<mark>.076</mark>				
Likelihood Ratio	506.249	1680	1.000				
Linear-by-Linear	1.393	1	.238				
Association							
N of Valid Cases	100						

Table(13)

The P value is larger than 0.05(alpha level) so, The null hypothesis will be accepted (that there is no significant association between the age of the patient and RDW value in this sample of heart failure patients).

11- The PDW values:

Chi-Square Tests						
	Value	Asymptotic				
			Significanc			
			e (2-sided)			
Pearson Chi-Square	2321.272ª	2200	<mark>.035</mark>			
Likelihood Ratio	555.901	2200	1.000			
Linear-by-Linear	.246	1	.620			
Association						
N of Valid Cases	100					

Table(14)

The P value is smaller than 0.05(alpha level) so, The null hypothesis will be rejected (that there is significant association between the age of the patient and PDW value in our sample of heart failure patients).

Symmetric Measures						
		Value	Approximate			
			Significance			
Nominal by	Cramer's V	<mark>.762</mark>	.035			
Nominal						
N of Valid Cas	ses	100				

Table(15)

As we have a high cramer's value(>0.5), there is strong association between the age of the patient and PDW value in this sample of heart failure patients.

The Effect Of Heart Failure On CBC Values:

1- The RBC value:

One-Sample Statistics						
N Mean Std. Std. Erro						
			Deviation	Mean		
RBC(×10^6/uL)	100	<mark>4.6344</mark>	.76571	.07657		

Table(16)

One-Sample Test					
Test Value = 4.8					
	t	df	Signif	Mean	
			One-	Two-	Difference
			Sided p	Sided p	
RBC(×10^6/uL)	-2.163	99	.016	.033	<mark>16560</mark>

Table(17)

As we see P value <0.05(alpha value) and mean difference is negative, that mean there is significant decrease in RBC count in this sample of heart failure patient.

2- The WBC value:

One-Sample Statistics					
N Mean Std. Std. Er					
			Deviation	Mean	
WBC(×10^3/uL)	100	10.4383	4.48664	.44866	

Γ	ab	le(1	8)

One-Sample Test					
Test Value = 7.5					
	t df Significance Mean				
			One-	Two-	Difference
			Sided p	Sided p	
WBC(×10^3/uL)	6.549	99	<.001	<mark><.001</mark>	<mark>2.93830</mark>

Table(19)

As we see P value <0.05(alpha value) and mean difference is positive, that mean there is significant increase in WBC count in this sample of heart failure patient.

3-The PLT value:

One-Sample Statistics						
N Mean Std. Std. Erro						
			Deviation	Mean		
PLT(×10^3/uL)	100	<mark>231.691</mark>	84.1380	8.4138		

Table(20)

One-Sample Test					
Test Value = 275					
	t df Significance Mean				
			One-	Two-	Difference
			Sided p	Sided p	
PLT(×10^3/uL)	-5.147	99	<.001	<mark><.001</mark>	<mark>-43.3090</mark>

Table(21)

As we see P value <0.05(alpha value) and mean difference is negative, that mean there is significant decrease in PLT in this sample of heart failure patient.

4- The HGB value:

One-Sample Statistics					
N Mean Std. Std. Error					
			Deviation	Mean	
HGB(g/dL)	100	<mark>12.671</mark>	2.0230	.2023	

Table(22)

One-Sample Test							
Test Value = 14.5							
	t df Significance Mean						
			One-	Two-	Difference		
			Sided p	Sided p			
HGB(g/dL)	-9.041	99	<.001	<mark><.001</mark>	<mark>-1.8290</mark>		

Table(23)

As we see P value <0.05(alpha value) and mean difference is negative, that mean there is significant decrease in HGB in this sample of heart failure patient.

The result may be not totally accurate due to the effect of the age of the patient on this value.

5- The HCT value:

One-Sample Statistics								
	N Mean Std. Std. Error							
			Deviation	Mean				
HCT(%)	100	<mark>39.4806</mark>	6.06082	.60608				

Table(24)

One-Sample Test								
	Test Value = 42.5							
	t	df	Signif	Mean				
			One-	Two-	Difference			
			Sided p	Sided p				
HCT(%)	-4.982	99	<.001	<mark><.001</mark>	<mark>-3.01940</mark>			

Table(25)

As we see P value <0.05(alpha value) and mean difference is negative, that mean there is significant decrease in HCT in this sample of heart failure patient.

6- The MCV value:

One-Sample Statistics						
N Mean Std. Std. Error						
			Deviation	Mean		
MCV(fL)	100	<mark>85.766</mark>	7.9073	.7907		

Table(26)

One-Sample Test								
	Test Value = 91							
	t	df	Signif	Mean				
			One-	Two-	Difference			
			Sided p	Sided p				
MCV(fL)	-6.619	99	<.001	<mark><.001</mark>	<mark>-5.2340</mark>			

Table(27)

As we see P value <0.05(alpha value) and mean difference is negative, that mean there is significant decrease in MCV in this sample of heart failure patient.

The result may be not totally accurate due to the effect of the age of the patient on this value.

7- The MCH value:

One-Sample Statistics						
N Mean Std. Std. Error						
			Deviation	Mean		
MCH(pg)	100	<mark>27.539</mark>	2.8273	.2827		

Table(28)

One-Sample Test							
	Test Value = 30.5						
	t	df	df Significance Me				
			One-	Two-	Difference		
			Sided p	Sided p			
MCH(pg)	-10.473	99	<.001	<mark><.001</mark>	<mark>-2.9610</mark>		

Table(29)

As we see P value <0.05(alpha value) and mean difference is negative, that mean there is significant decrease in MCH in this sample of heart failure patient.

8- The MCHC value:

One-Sample Statistics					
N Mean Std. Std. Error					
			Deviation	Mean	
MCHC(g/dL)	100	<mark>32.141</mark>	1.5027	.1503	

Table(30)

One-Sample Test							
Test Value = 33.5							
	t df Significance Mean						
			One-	Two-	Difference		
			Sided p	Sided p			
MCHC(g/dL)	-9.044	99	<.001	<mark><.001</mark>	<mark>-1.3590</mark>		

Table(31)

As we see P value <0.05(alpha value) and mean difference is negative, that mean there is significant decrease in MCHC in this sample of heart failure patient.

9- The RDW value:

One-Sample Statistics							
	N Mean Std. Std. Error						
			Deviation	Mean			
RDW(%)	100	<mark>15.998</mark>	2.7824	.2782			

Table(32)

One-Sample Test								
	Test Value = 13.5							
	t	df	Signif	Mean				
			One-	Two-	Difference			
			Sided p	Sided p				
RDW(%)	8.978	99	<.001	<mark><.001</mark>	<mark>2.4980</mark>			

Table(33)

As we see P value <0.05(alpha value) and mean difference is positive, that mean there is significant increase in RDW in this sample of heart failure patient.

10- The MPV value:

One-Sample Statistics								
	N Mean Std. Std. Error							
			Deviati	Mean				
			on					
MPV(fL)	100	<mark>10.1698</mark>	1.22445	.12244				

Table(34)

One-Sample Test							
	Test Value = 9.25						
	t	df	Signif	Mean			
			One-	Two-	Difference		
			Sided p	Sided p			
MPV(fL)	7.512	99	<.001	<mark><.001</mark>	<mark>.91980</mark>		

Table(35)

As we see P value <0.05(alpha value) and mean difference is positive, that mean there is significant increase in MPV in this sample of heart failure patient.

11- The PDW value:

One-Sample Statistics						
	N	Mean	Std.	Std. Error		
			Deviation	Mean		
PDW(%)	100	<mark>39.361</mark>	2.0385	.2038		

Table(36)

One-Sample Test									
Test Value = 40.7									
	t	df	Significance		Mean				
			One-	Two-	Difference				
			Sided p	Sided p					
PDW(-6.569	99	<.001	<mark><.001</mark>	<mark>-19.3390</mark>				
%)									

Table(37)

As we see P value <0.05(alpha value) and mean difference is negative, that mean there is significant decrease in PDW in this sample of heart failure patient.

The result may be not totally accurate due to the effect of the age of the patient on this value.

The total result may be not totally accurate due to some limitations that we will discuss later.

Discussion:

In our study, HF patients males were more than female (74% versus 26%).

The predominance of HF in male may be attributed to high incidence of IHD in male and the effect of oestrogen protection against cardiovascular diseases in females [6][8].

But regarding the CBC of the patients there is no significant association between the gender and CBC variable values in this sample of heart failure patients. In regards to age of the patients, the mean age of the patients in our study was 59.9. In this study most of the patients with HF were the age groups of 50-60 years and > 65 years and this supports the high prevalence of this condition in the older population [7].

The effects of heart failure on CBC values were as follows:

1-RBCs count and HGB concentration:

As seen in the results, the mean difference is negative in both variables means there is a decrease in both of these variables in HF patients in this sample of heart failure patients. and this decrease is significant (p value is <0.05). There are many causes of anaemia in HF patients and these are:

- Bone marrow depression from excessive cytokine production.
- Malnutrition (Missing certain vitamins or minerals in the diet because the patient is not eating enough) [9].
- Kidney disease (when kidneys are diseased they produce less erythropoietin, a hormone that signals the bone marrow to make RBCs) [9].
- Drug therapy (such as ACE inhibitors, antihypertensive drugs) [9].

The incidence of anemia is higher in women, diabetic patients, elderly and patients with chronic kidney diseases. This result agrees with Raed Odeh, M.B. Bdeir and Tara Conboy research (Prevalence of anemia in a Saudi population with chronic heart failure), In this study, the number of patients was 1256 and at admission, 27% (337) of patients were anaemic, with higher prevalence in females (33.4%) [10].

2-hematocrit level HCT :

As seen in the results, the mean difference is negative means there is decrease in HCT in this sample of HF patients. And the decreased HCT in HF patients is due to increased plasma volume (hemodilution) or from low RBCs count. This result agree with Maya Guglin research, University of South Florida (Relationship of Haemoglobin and Hematocrit to Systolic Function in Advanced Heart Failure), this study shows that there is correlation between HCT and HB, in this study Out of 433 patients , both HB and HCT were decreased in 37–43% of the HF population [11].

3-mean cell volume MCV and mean cell hemoglobin MCH:

As seen in the results the mean difference is negative in both of these variables means there is decreased MCV and MCH levels in this sample of HF patients. So the patients have microcytic hypochromic anemia. This condition may be caused by iron deficiency [12]. And this result agree with Shimaa G. Mohammed, Abdel Hamead M. Mousa and Alaa M. Hashim research (Role of Hypochromia and Microcytosis in the prediction of iron deficiency anemia), this study shows that the serum iron levels in 60 cases (out of 90 patients) with hypochromia and microcytosis with normal haemoglobin were reduced it indicates an early sign of iron deficiency anemia [13].

4- red blood cell distribution width RDW:

As seen in the results the mean difference is positive means there is an increased RDW in this sample of HF patients. This increase is not significant (p value is < 0.05). Several pathophysiological mechanisms have been implicated in increasing RDW in HF patients such as ageing, oxidative stress, inflammation, kidney disease, iron deficiency and nutritional deficiencies [14]. RDW is a powerful mortality predictor in elderly. Our result agree with Antoine Garnier, Julien Regamey, Olivier Hugli and David Martin clinical research (Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction), this result shows that patients with high RDW were older, had a higher incidence of previous HF-related hospitalizations. Patients in the high RDW had lower LVEF, lower systolic and diastolic blood pressure, and lower haemoglobin. Creatinine, C-reactive protein, and NT-proBNP levels were higher [15].

5-platelets count:

As seen in the results the mean difference is negative means there is decrease in platelets count in this sample of HF patients. platelet counts are used as a prognostic marker in the assessment of the patient with Heart failure. The causes of thrombocytopenia are: bone marrow depression, drug therapy particularly with intravenous blood heparin (heparin induced thrombocytopenia) and also the drugs that regulate the blood clotting (antiplatelet drugs) **[16]**.

Our result agree with Mohammad Khalid Mojadidi research (Thrombocytopenia as a Prognostic Indicator in Heart Failure with Reduced Ejection Fraction), in this study 1907 patients with HF, overall one-year mortality was 17.2% with higher mortality among patients with moderate/severe thrombocytopenia compared to those with normal/mild thrombocytopenia (33.0% vs. 15.4%) [17].

6-mean platelet volume MPV:

As seen in the results MPV value is increased in this sample of HF patients (the mean difference is positive). MPV is also a useful prognostic biomarker in patients with cardiovascular diseases [18].

7-platelet distribution width PDW:

As seen in the results the PDW is decreased (mean difference is negative). PDW is a specific marker for platelet activation. The prognostic impact of PDW is unclear in patients with HF. Reduced PDW in this sample of HF patients may be due to bone marrow cells (including megakaryocytes) malfunctioning [19].

Conclusion:

- Anaemia is highly prevalent in patients with HF particularly, in the elderly and in females. Anaemic patients had worse symptoms and higher overall mortality than none anaemic.
- In patients with HF, higher degree of thrombocytopenia is associated with higher all-cause mortality. These findings may support the use of platelet counts as a prognostic marker in the assessment of the patient with heart failure.
- High RDW is associated with a high mortality rate in HF patients.

Limitations

1- The few heart failure patients that present in the hospital made a challenge to us so, we decided to get the information of heart failure patients form the patient's files in the archives of the hospital so, we can't anymore calculate the BMI of the patients in our research.

2-Some of CBC sheets have PDW-sd and do not have PDW-cv, others have PDW-cv and do not have PDW-sd.

Since we decide to use PDW-cv in our research, we have to switch PDW-sd values to PDW-cv but we do not have the standard deviation that is important to do this calculation by the formula [PDW-cv=(SD/MPV)×100%], so, we needed other solution.

For that reason we made other formula that do not need the standard deviation to do this calculation by the following mathematic theorem:

 \therefore PDW-sd = X

PDW-cv = Y

ng = Normal range

ngw = Normal range width

- $:: X_{ng} = (9fL \text{ to } 17fL)$
- $\therefore X_{ngw} = 17-9=8(fL)$
- $:: Y_{ng} = (37.8\% \text{ to } 43.6\%)$
- \therefore Y_{ngw} = 37.8-43.6=5.8(%)

 $\therefore Z = X_{ngw} \times Y_{ngw}$

 \therefore A-C/X_{ngw} = B-D/Y_{ngw}

 $\lor A \in X, B \in Y$

C = Lower value of X_{ng}

D = Lower value of Y_{ng}

 $\therefore X_{ngw} = 8(fL), Y_{ngw} = 5.8(\%)$

C = 9(fL), D = 37.8(%)

 \therefore A(Fl)-9(fL)/8(fL) = B(%)-37.8(%)/5.8(%)

■ B(%) = $[(A_{(fL)-9}) \div 8] \times 5.8 + 37.8$

3- We supposed to find the mean of CBC values of normal population that we need for our calculation, because we failed to get normal population CBC test, we made the formula[X_{mean} =[(A+B)÷2]+B] for this calculation by the following mathematic theorem:

 \therefore X= one of CBC values.

 \therefore X has known normal rang (ng).

 \therefore X value for most population (mp) is in the middle of (ng) according to bell curve.

 $\therefore X_{mean}=X_{mp}$

 $:: X_{mp} = (X_{ng} \div 2) + B$

∨ A = grater value of(ng)

B = smaller value of (ng)

 $::X_{ng} = A - B$

 $\therefore X_{mp} = [(A - B) \div 2] + B$

 $X_{mean} = [(A-B) \div 2] + B$

4-Most of the patients were unconscious, so we couldn't take enough information from the patients.

5-The cases were few, so we had to go to more than one hospital to find cases.

Recommendations:

- Further studies among other hospitals and societies are needed about the effects of heart failure on kidney functions or lung functions.
- Further studies about the effect of heart failure on liver function tests are needed.
- Also studies about relationships of heart failure and hypertension.

References:

1- American heart association. (2016). What is heart failure? Retrieved from source.

2- American heart association. (2020). Arrhythmia. Retrieved from source.

3- Braunwald, E. (2008). Heart failure. In harrison's principles of internal medicine (17th ed., Vol. 1). McGraw-Hill professional.

4-Mayo Clinic(Heart failure - Symptoms and causes-)

5-IBM Crop. (2020). IBM SPSS Statistics for Windows, Version 29.0.0.0. Armonk, NY:IBM Crop.

6- Mielczarek, M., Nowak, A., & Pilaczyńska-Cemel, M. (2016). Sex differences in heart failure. Kardiochirurgia i Torakochirurgia Polska, 13(4), 348-353.

7- Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang,
A. R., Cheng, S., ... & Khan, S. S. (2018). Heart disease and stroke statistics—
2018 update: a report from the American Heart Association. Circulation, 137(12), e67-e492.

8- Regitz-Zagrosek, V., & Seeland, U. (2014). Sex and gender differences in myocardial hypertrophy and heart failure. Circulation Journal, 78(10), 2347-2353.

9-Gheorghiade, M., & Vaduganathan, M. (2020). Diagnosis and management of acute heart failure syndromes. Cardiology Clinics, 38(4), 397-410.

10- Odeh, R., Bdeir, M. B., & Conboy, T. (2013). Prevalence of anemia in a Saudi population with chronic heart failure. Saudi Medical Journal, 34(10), 1032-1038.

11- Braunwald, E. (2013). Heart failure. Journal of the American College of Cardiology, 61(4), 391-403.

12- Von Haehling, S., Jankowska, E. A., & Anker, S. D. (2014). Iron deficiency and cardiovascular disease. Nature Reviews Cardiology, 11(3), 165-173.

13-Mohammed, S. G., Mousa, A. H., & Hashim, A. M. (2017). Role of hypochromia and microcytosis in the prediction of iron deficiency anemia. Journal of Medical Laboratory and Diagnosis, 8(4), 9-18.

14-Allen, L. A., Felker, G. M., & Mehra, M. R. (2010). Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. Journal of Cardiac Failure, 16(3), 230-238.

15-Garnier, A., Regamey, J., Hugli, O., & Martin, D. (2019). Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction. European Heart Journal: Acute Cardiovascular Care, 8(3), 253-262.

16-Ammann, E. M., & Thürmel, K. (2019). Acquired thrombocytopenia. Deutsches Ärzteblatt International, 116(35-36), 593-599.

17-Mojadidi, M. K., Elgendy, I. Y., Mahmoud, A. N., Elgendy, A. Y., Bavry, A. A., & Hohmann, S. F. (2018). Thrombocytopenia as a prognostic indicator in heart failure with reduced ejection fraction. Journal of the American Heart Association, 7(14), e009563.

18-Danese, E., Montagnana, M., & Lippi, G. (2016). Platelets and cardiovascular disease: A pathophysiological and clinical overview. Seminars in Thrombosis and Hemostasis, 42(3), 268-280.

19-Montoro-García, S., & Shantsila, E. (2014). Platelets and cardiovascular risk. European Cardiology Review, 9(2), 97-106.

(questionnaire):

- 1- sample no. :
- 2- Gender :
- 3-Age :
- 4-Height:
- 5-weight:
- 6- BMI :
- 7- CBC : -RBC (red blood cells) :
 - -WBC (white blood cells) :
 - -PLT (platlets) :
 - -HB (hemoglobin) :
 - -HCT (hematocrit) :
 - -MCV (mean cell volume) :
 - -MCH (mean cell hemoglobin) :
 - -MCHC (mean cell hemoglobin concentration) :
 - -RDW (red cell distribution width):
 - -MPV (mean platlets volume) :
 - -PDW (platlet distribution width) :